- Quarterly Report (10-Q)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934

For the quarterly period ended June 30, 2009

[ ] TRANSACTION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NO. 001-33088

IVIVI TECHNOLOGIES, INC.
(Name of Small Business Issuer in its Charter)

 New Jersey 22-2956711
 (State or Other Jurisdiction (I.R.S. Employer
of Incorporation or organization) Identification
 Number)

135 Chestnut Ridge Rd., Montvale, New Jersey 07645
(Address of Principal Executive Offices)

Issuer's Telephone Number, including area code: (201) 476-9600

Indicate by check mark whether the Issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the Issuer was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:

YES [X] NO [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES [ ] NO [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ]
Non-accelerated filer [ ] Smaller reporting
 company [X]
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act)

YES [ ] NO [X]

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date:

11,241,033 shares of Common Stock, no par value, as of September 13, 2009

IVIVI TECHNOLOGIES, INC.
INDEX

Part I. Financial Information Page No.

Item 1. Financial Statements:

 Balance Sheets as of June 30, 2009 (Unaudited) and
 March 31, 2009 3

 Statements of Operations for the three months ended
 June 30, 2009 and 2008 (Unaudited) 4

 Statement of Stockholders' Equity for the three months
 ended June 30, 2009 (Unaudited) 5

 Statements of Cash Flows for the three months ended
 June 30, 2009 and 2008 (Unaudited) 6

 Notes to the Financial Statements (Unaudited) 7

Item 2. Management's Discussion and Analysis of Financial Condition
 and Results of Operations 23

Item 3. Quantitative and Qualitative Disclosures about Market Risk 40

Item 4. Controls and Procedures 40

Part II. Other Information 42

Item 1. Legal Proceedings 42

Item 1A. Risk Factors 43

Item 6. Exhibits 44

 Signatures 48

PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS

 IVIVI TECHNOLOGIES, INC.
 BALANCE SHEETS


 JUNE 30, 2009 MARCH 31, 2009
 ------------ ------------
 (UNAUDITED)
 ASSETS
Current assets:
 Cash and cash equivalents $ 771,737 $ 220,136
 Accounts receivable, net of allowance for doubtful
 accounts of $0 and $40,500 respectively 129,504 98,314
 Inventory 117,081 178,379
 Deposits with and amounts due from affiliate 72,555 104,321
 Prepaid insurance 61,989 86,708
 Prepaid expenses 7,213 53,646
 Receivable relating to litigation settlement 350,000 350,000
 Other current assets -- 30,408
 ------------ ------------

 Total current assets 1,510,079 1,121,912

Property and equipment, net 289,836 313,413
Equipment in use or under rental agreements, net 25,720 34,656
Inventory long-term, net of reserves of $633,026
 and $633,026, respectively 111,243 33,110
Intangible assets, net of accumulated amortization
 of $82,392 and $81,641, respectively 882,540 812,253
Restricted cash 49,712 49,441
 ------------ ------------

 $ 2,869,130 $ 2,364,785
 ============ ============

 LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
 Accounts payable and accrued expenses $ 1,284,574 $ 1,378,048

Convertible debt, net of unamortized discount of $1,506,904 493,096 --
 ------------ ------------

 Total current liabilities 1,777,670 1,378,048
 ------------ ------------

Deferred revenue 35,640 35,640
 ------------ ------------

Stockholders' equity:
 Preferred stock, no par value, 5,000,000 shares
 authorized, no shares issued and outstanding -- --
 Common stock, no par value; 70,000,000 shares
 authorized, 11,241,033 and 11,241,033 shares issued
 and outstanding, respectively 26,199,461 26,199,461
 Additional paid-in capital 15,349,520 13,398,213
 Accumulated deficit (40,395,661) (38,549,077)
 Treasury stock, at cost, 650,000 and 650,000 shares
 outstanding, respectively (97,500) (97,500)
 ------------ ------------

 1,055,820 951,097
 ------------ ------------

 $ 2,869,130 $ 2,364,785
 ============ ============


 The accompanying notes are an integral part of these unaudited financial statements.

 3

 IVIVI TECHNOLOGIES, INC.
 STATEMENTS OF OPERATIONS
 FOR THE THREE MONTHS ENDED JUNE 30,


 2009 2008
 ------------ ------------
 (UNAUDITED) (UNAUDITED)
Revenue:
 Rentals $ 4,380 $ 168,736
 Direct sales 38,701 99,049
 Sales and revenue share on RecoverCare contract 91,277 --
 Licensing sales and fees on Allergan contract -- 115,411
 ------------ ------------

 134,358 383,196
 ------------ ------------

Costs and expenses:
 Cost of rentals -- 10,214
 Cost of direct sales 6,308 12,260
 Cost of sales on RecoverCare contract 12,373 --
 Cost of licensing sales on Allergan contract -- 129,770
 Research and development 493,755 531,068
 Sales and marketing 92,571 677,222
 General and administrative 821,800 1,270,137
 ------------ ------------

 1,426,807 2,630,671
 ------------ ------------

Loss from operations (1,292,449) (2,247,475)
Interest income 3,711 45,160
Interest expense (557,846) --
 ------------ ------------

Net loss $ (1,846,584) $ (2,202,315)
 ============ ============

Net loss per share, basic and diluted $ (0.16) $ (0.21)
 ============ ============

Weighted average shares outstanding 11,241,033 10,715,130
 ============ ============

 The accompanying notes are an integral part of these unaudited financial statements.


 4

 IVIVI TECHNOLOGIES, INC.

 STATEMENTS OF STOCKHOLDERS' EQUITY
 FOR THE THREE MONTHS ENDED JUNE 30, 2009
 (UNAUDITED)



 Common Stock Additional Total
 ----------------------------- Paid-In Accumulated Treasury Stockholders'
 Shares Amount Capital Deficit Stock Equity
 ------------ ------------ ------------ ------------ ------------ ------------

Balance - April 1, 2009 11,241,033 $ 26,199,461 $ 13,398,213 $(38,549,077) $ (97,500) $ 951,097

Issuance of convertible debt
to Emigrant Capital Corp.,
net of issuance costs of
$180,000 1,820,000 1,820,000

Share based compensation 131,307 131,307

Net loss (1,846,584) (1,846,584)
 ------------ ------------ ------------ ------------ ------------ ------------

Balance - June 30, 2009 11,241,033 $ 26,199,461 $ 15,349,520 $(40,395,661) $ (97,500) $ 1,055,820
 ============ ============ ============ ============ ============ ============


 The accompanying notes are an integral part of these unaudited financial statements.

 5

 IVIVI TECHNOLOGIES, INC.

 STATEMENTS OF CASH FLOWS
 FOR THE THREE MONTHS ENDED JUNE 30,
 (UNAUDITED)
 2009 2008
 ----------- -----------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(1,846,584) $(2,202,315)
Adjustments to reconcile net loss to net cash used by
 operating activities:
 Depreciation and amortization 28,500 69,365
 Share based compensation 131,307 309,535
 Amortization of deferred revenue -- (15,625)
 Accretion of debt discount 493,096 --
 Bad debt recovery (40,500) --
 Other -- (715)
Changes in operating assets and liabilities:
 (Increase) decrease in:
 Accounts receivable 9,310 187,193
 Deposits with and amounts due from affiliate 31,766 96,664
 Inventory (16,835) (138,312)
 Equipment in use and under rental agreements 4,764 (7,570)
 Prepaid expenses and other current assets 101,560 28,177
 Decrease in:
 Accounts payable and accrued expenses (93,474) (34,109)
 ----------- -----------
 (1,197,090) (1,707,712)
 ----------- -----------
CASH FLOWS FROM INVESTING ACTIVITIES:
 Purchases of property and equipment -- (7,975)
 Increase in restricted cash (271) --
 Payments for patents and trademarks (71,038) (96,218)
 ----------- -----------
 (71,309) (104,193)
 ----------- -----------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debt to Emigrant Capital Corp.,
 net of issuance costs of $180,000 1,820,000 --
 ----------- -----------
 1,820,000 --
 ----------- -----------

Net increase (decrease) in cash and cash equivalents 551,601 (1,811,905)
Cash and cash equivalents, beginning of period 220,136 6,600,154
 ----------- -----------

Cash and cash equivalents, end of period $ 771,737 $ 4,788,249
 =========== ===========


 The accompanying notes are an integral part of these unaudited financial statements.

IVIVI TECHNOLOGIES, INC.

NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2009
(UNAUDITED)

NOTE 1 -- BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

BASIS OF PRESENTATION

The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and the instructions to Form 10-Q for smaller reporting companies (as defined in Rule 12b-2 of the Exchange Act) and do not include all the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation of the results for the interim periods have been included. Operating results for the three months ended June 30, 2009 are not necessarily indicative of the results that may be expected for the fiscal year ending March 31, 2010.

The accompanying financial statements and related notes and the information included under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations" should be read in conjunction with our audited financial statements and related notes thereto included on our Annual Report on Form 10-K for the fiscal year ended March 31, 2009.

GOING CONCERN
The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, we had a net loss of $1,846,584 and $2,202,315, respectively, for the quarters ended June 30, 2009 and 2008 and a working capital deficiency of $267,591 at June 30, 2009. We had a net loss of $7,333,604 and $7,503,091, respectively, for the fiscal years ended March 31, 2009 and 2008 and a working capital deficiency of $256,136 at March 31, 2009. At June 30, 2009, we had cash balances of approximately $772,000 which is not sufficient to meet our current cash requirements for the next twelve months. On April 7, 2009, we closed on a $2.5 million loan with Emigrant Capital Corp. (see Note 2 - Loan Agreement). However, we were not able to generate sufficient cash flow from our operations to repay principal on this loan of $2,500,000 plus interest on August 30, 2009.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

On September 2, 2009, we announced that we had entered into a Forbearance Agreement (the "Forbearance Agreement") dated August 31, 2009 with Emigrant Capital Corp. (the "Lender"). Pursuant to the terms of the Forbearance Agreement, the Lender had agreed to forbear, through September 9, 2009 (unless a termination event occurred under the Forbearance Agreement), from requiring us to repay the principal and interest due under the Convertible Promissory Note (the "Note") in the principal amount of $2.5 million. The maturity date under the Note was August 30, 2009. The Forbearance Agreement also provided for an increase in the interest rate under the Note to the lesser of (i) 18% or (ii) the maximum rate permitted by law during the forbearance period. The Lender agreed to the forbearance in order to provide us with the ability to continue (i) negotiating the previously announced potential transaction with Ajax Capital, LLC ("Ajax"), an entity owned by Steven Gluckstern, our Chairman, President, Chief Executive Officer and Chief Financial Officer, and
(ii) solicit other proposals.

Effective September 9, 2009, we and the Lender amended the terms of the Forbearance Agreement to extend the forbearance period through September 14, 2009. Other than the change in the forbearance period, there were no other amendments or changes to the Forbearance Agreement.

On September 14, 2009, we and the Lender amended the terms of the Forbearance Agreement to extend the forbearance period through September 16, 2009 and on September 16, 2009, we and the Lender amended the terms of the Forbearance Agreement to further extend the forbearance period through September 21, 2009. Other than the aforementioned changes in the forbearance period, there were no other amendments or changes to the Forbearance Agreement.

We are currently negotiating the terms of a proposed Asset Purchase Agreement (the "Asset Purchase Agreement") with Ivivi Technologies, LLC (the "Buyer") and Ajax Capital, LLC ("Ajax"), entities controlled by Steven M. Gluckstern, our Chairman, President, Chief Executive Officer and Chief Financial Officer. Pursuant to the terms of such proposed Asset Purchase Agreement, at the closing, we would sell substantially all of our assets to the Buyer, other than cash and certain other excluded assets, and the Buyer would assume certain specified ordinary course liabilities of ours as set forth in such Asset Purchase Agreement. The aggregate purchase price to be paid to us under the terms of the proposed Asset Purchase Agreement is expected to equal the sum of (i) the amount necessary to pay in full the principal, and accrued interest, as of closing, under our loan with the Lender, which was approximately $2,611,834 as of September 15, 2009 (the "Loan") and (ii) $475,000; provided, however, that the sum of the a mounts specified in clauses (i) and (ii) would not be in excess of $3.15 million. The closing of the transactions contemplated by the proposed Asset Purchase Agreement would be subject to certain customary conditions, including the receipt of approval by our shareholders of the transactions contemplated by the proposed Asset Purchase Agreement.

Under the terms of the proposed Asset Purchase Agreement, we and Foundation Ventures, LLC ("Foundation"), our investment banker, would continue to have the right to solicit other proposals regarding the sale of our assets and equity until receipt of the approval by our shareholders of the transactions contemplated by such Asset Purchase Agreement. Prior to the receipt of approval by our shareholders, we would also have the right to terminate the transaction under specified circumstances in order to enter into a definitive agreement implementing a Superior Proposal (to be defined in the Asset Purchase Agreement). If we terminate the transactions with the Buyer to enter into a Superior Proposal, we would be required to pay the Buyer a termination fee equal to $90,000.

In connection with the signing of the Asset Purchase Agreement, the Buyer, us and certain of our shareholders, who have the power to vote approximately 39.5% (and together with our common stock held by Steven M. Gluckstern, approximately 51.3%) of our common stock, would be required to enter into a Voting Agreement (each, a "Voting Agreement"). Pursuant to each Voting Agreement, the signatory shareholders would agree to vote their shares of our common stock in favor of the transactions contemplated by the Asset Purchase Agreement. In the event that we terminate the transactions with the Buyer in connection with a Superior Proposal, the Voting Agreements would also terminate.

We are also currently negotiating an Amended and Restated Forbearance Agreement with our Lender under which the Lender would agree to extend the forbearance period in order for us to complete the transactions contemplated by the proposed Asset Purchase Agreement.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

There is no assurance that we will be able to complete the negotiations of the proposed Asset Purchase Agreement or the proposed Amended and Restated Forbearance Agreement or what the final terms under such agreements will be. In addition, even if we enter into the Asset Purchase Agreement, we may not be able to complete the transactions contemplated by such proposed Asset Purchase Agreement. In the event the transaction with the Buyer is completed, following the closing, it is likely that our liabilities will exceed our available cash and our board of directors may elect to liquidate us and utilize our available cash and assets to repay our outstanding creditors to the extent of our remaining assets and then distribute any remaining assets, if any, to our shareholders. In addition, following the closing we will remain liable under our lease for our Montvale, New Jersey office. The lease, which has a monthly rent of $15,613, will terminate in October 2014. Payments on the lease are current as of the date of this filing.

In the event we do not successfully complete the negotiation of the proposed Asset Purchase Agreement or the proposed Amended and Restated Forbearance Agreement and complete the transactions contemplated by such agreements or complete another transaction, we will not be able to meet our obligations under the Loan and the Lender will have the right to foreclose under the Loan, which is secured by all of our assets. In such an event, we would have to cease our operations or file for bankruptcy protection.

In the fourth quarter of 2008, we retained two firms, including Foundation, to assist us in pursuing alternative strategies and financings relating to our business. In December 2008, we terminated our relationship with one of the firms. Through June 30, 2009, we paid $130,000 and issued warrants to one of the entities including $100,000 of fees relating to our Loan Agreement. Additional fees of $150,000 were paid to these entities subsequent to June 30, 2009, including $125,000 of fees relating to our current transaction being negotiated. Additional fees may be due to Foundation in the event of a Superior Proposal or other future successful financing or other transactions by us.

These factors, among others, raise substantial doubt about our ability to continue as a going concern, which will be dependent on our ability to raise additional funds to finance our operations or seek alternative transactions. The accompanying financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

ORGANIZATIONAL MATTERS

ORGANIZATION

Ivivi Technologies, Inc. ("We", "Us", "the Company" or "Ivivi"), formerly AA Northvale Medical Associates, Inc., was incorporated under the laws of the state of New Jersey on March 9, 1989. We are authorized under our Certificate of Incorporation to issue 70,000,000 common shares, no par value, and 5,000,000 preferred shares, no par value.

NATURE OF BUSINESS

We sell and rent non-invasive electro-therapeutic medical devices. These products are sold or rented primarily through our distributors and customers located in the United States with additional markets in Mexico.

Our medical devices are subject to extensive and rigorous regulation by the FDA, as well as other federal and state regulatory bodies. On December 15, 2008, we announced that we had received FDA 510(k) clearance for our currently marketed targeted pulsed electromagnetic field (tPEMF(TM)) therapeutic products.

NASDAQ DELISTING

On June 23, 2009, our common stock was suspended from trading on the Nasdaq Stock Market. On June 26, 2009, our common stock commenced trading on the OTC Bulletin Board under the symbol IVVI.OB.

FDA MATTERS

On April 3, 2008, we filed a 510(k) submission with the Food and Drug Administration (FDA) for a small, compact transcutaneous electrical nerve stimulation(TENS)product utilizing our targeted pulsed electromagnetic field (tPEMF) therapy technology for the symptomatic relief and management of chronic, intractable pain, for relief of pain associated with arthritis and for the adjunctive treatment of post-surgical and post-trauma acute pain. The FDA requested additional information from us in a letter dated April 25, 2008. During October 2008, we requested a voluntary withdrawal of this 510(k).

On December 15, 2008, we announced that we had received FDA 510(k) marketing clearance for our currently marketed tPEMF therapeutic SofPulse products.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

On April 9, 2009, the FDA issued an order to manufacturers of remaining pre-amendments class III devices (including shortwave diathermy devices not generating deep heat, which is the classification for our SofPulse devices) for which regulations requiring submission of Premarket Approval Applications (PMA) have not been issued. The order requires the manufacturers to submit to the FDA, a summary of, and a citation to, any information known or otherwise available to them respecting such devices, including adverse safety or effectiveness information concerning the devices which has not been submitted under the Federal Food, Drug, and Cosmetic Act. The FDA is requiring the submission of this information in order to determine, for each device, whether the classification of the device should be revised to require the submission of a PMA or a notice of completion of a Product Development Protocol ("PDP"), or whether the device should be reclassified into class I or II. Summaries and citations were due by August 7, 2009. We submitted our summary with citations to the FDA on August 7, 2009 for our shortwave diathermy devices not generating deep heat, complying with this order. Our products are being marketed during this process.

On July 2, 2009, we filed a 510(k) submission for marketing clearance with the FDA for a TENS device known as ISO-TENS which uses tPEMF technology. This new device is proposed for commercial distribution for the symptomatic relief of chronic intractable pain; adjunctive treatment of post-surgical or post traumatic acute pain; and adjunctive therapy in reducing the level of pain associated with arthritis. We believe the ISO-TENS will enable penetration into various chronic pain markets if FDA clearance is obtained. The FDA requested additional information related to this submission which has been provided.

FAIR VALUE OF FINANCIAL INSTRUMENTS

FASB No. 157, "Fair Value Measurements" (Statement No. 157), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Statement No. 157 applies to other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. In February 2008, the FASB issued FASB Staff Position 157-2, which provides for a one-year deferral of the provisions of Statement No. 157 for non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a non-recurring basis. Effective April 1, 2008, we adopted the provisions of Statement No. 157 for financial assets and liabilities, as well as for any other assets and liabilities that are carried at fair value on a recurring basis. The adoption of the provisions of Statement No. 157 related to financial assets and liabilities and other assets and liabilities that are carried at fair value on a recurring basis did not materially impact the company's financial position and

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

results of operations. For certain of our financial instruments, including accounts receivable, inventories, accounts payable and accrued expenses, the carrying amounts approximate fair value due to their relatively short maturities.

In February 2007, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 159 ("FAS 159"), The Fair Value Option for Financial Assets and Financial Liabilities, which permits entities to choose to measure many financial instruments and certain other items at fair value which are not currently required to be measured at fair value. Effective April 1, 2008, we adopted the provisions of Statement No. 159 for financial assets and liabilities. The adoption of the provisions of Statement No. 159 related to financial assets and liabilities that are carried at fair value on a recurring basis did not materially impact the company's financial position and results of operations.

RECLASSIFICATIONS

Certain items in the prior period financial statements have been reclassified to conform to the current period presentation. Such reclassifications have had no impact on previously reported total assets, equity, revenues and net loss.

INTANGIBLE ASSETS

Intangible assets consist of patents and trademarks of $882,540, net of accumulated amortization of $82,392 at June 30, 2009. Amortization expense of patent and trademarks totaled $751 and $23,027 for the quarters ended June 30, 2009 and 2008, respectively. Patents and trademarks are amortized over their legal life once they are issued by the U.S. or other governmental patent and trademark office.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

At June 30, 2009, accounts payable and accrued expenses consisted of the following:

 Total
 -----
Research and development $ 450,007
Professional fees 341,004
Intellectual Property 101,877
Compensation and Employee Benefits 73,322
Insurances 67,938
Interest on convertible debt 64,750
Consulting 44,027
Accrued rent 34,112
Deposits with RecoverCare 14,445
Other 93,092
 ------------

 $ 1,284,574
 ============

At June 30, 2009, our Accounts Payable and Accrued Expenses on our Balance Sheet includes $14,445 of deposits received from RecoverCare which is the upfront fee of $535 for each of the 27 Roma units held by RecoverCare on that date and which were not placed into service by them at June 30, 2009.

LOSS PER SHARE

We use SFAS No. 128, "Earnings Per Share" for calculating the basic and diluted loss per share. We compute basic loss per share by dividing net loss and net loss attributable to common shareholders by the weighted average number of common shares outstanding. Diluted loss per share is computed similar to basic loss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential shares had been issued and if the additional shares were dilutive. Common equivalent shares are excluded from the computation of net loss per share since their effect is anti-dilutive.

Per share basic and diluted net loss amounted to $0.16 for the quarter ended June 30, 2009 and $0.21 for the quarter ended June 30, 2008. There were 6,363,534 potential shares and 6,068,656 potential shares that were excluded from the shares used to calculate diluted earnings per share, as their inclusion would reduce net loss per share, for the quarters ended June 30, 2009 and 2008, respectively.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

COMMON SHARE OPTIONS AND WARRANTS ISSUED SHARE BASED COMPENSATION

We follow the provisions of SFAS 123(R) "SHARE-BASED PAYMENT," using the modified prospective method. Under this method, we recognized compensation cost based on the grant date fair value, using the Black Scholes option value model, for all share-based payments granted on or after April 1, 2006 plus any awards granted to employees prior to April 1, 2006 that remained unvested at that time.

We use the fair value method for equity instruments granted to non-employees and use the Black Scholes option value model for measuring the fair value of warrants and options. The share-based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the periods in which the related services are rendered.

As of June 30, 2009, we have used the following assumptions in the Black Scholes option pricing model: (i) dividend yield of 0%; (ii) expected volatility of 44%-287.5%; (iii) average risk free interest rate of 1.78%-5.03%; (iv) expected life of 1 to 6.5 years; and (v) estimated forfeiture rate of 5%. The foregoing option valuation model requires input of highly subjective assumptions. Because common share purchase options granted to employees and directors have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value of estimates, the existing model does not in the opinion of our management necessarily provide a reliable single measure of the fair value of common share purchase options we have granted to our employees and directors.

During the quarters ended June 30, 2009 and 2008, our share based compensation expense was allocated to the following Statement of Operations classifications:

 2009 2008
 -------- --------
Cost of rentals $ -- $ 11
Research and development 25,015 16,858
Sales and marketing 18,458 20,878
General and administrative 87,834 271,788
 -------- --------

 $131,307 $309,535
 ======== ========

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

NOTE 2 - LOAN AGREEMENT

On April 7, 2009, we closed on our $2.5 million loan (the "Financing") with the Lender. Under the terms of the loan agreement between us and the Lender (the "Loan Agreement"), we have borrowed an aggregate of $2.5 million. Borrowings under the Financing are evidenced by a note (the "Note"), which bears interest at a rate of 12% per annum (which, as previously disclosed, increased to 18% after August 30, 2009) in connection with the Forbearance Agreement described in Note 1). See Note 1 for a description of the Forbearance Agreement. The Note is currently convertible into our common stock at a conversion price of $0.23 per share.

In connection with the Financing, we issued warrants to the Lender (the "Warrants"). The Warrants are currently exercisable for $3.0 million of our common stock at an exercise price of $0.23 per share. The Warrants also provide for cashless exercise.

In addition to customary mechanical adjustments with respect to stock splits, reverse stock splits, recapitalizations, stock dividends, stock combinations and similar events, the Note and the Warrants provide for certain "weighted average anti-dilution" adjustments whereby if shares of our common stock or other securities convertible into or exercisable or exchangeable for shares of our common stock (such other securities, including, without limitation, convertible notes, options, stock purchase rights and warrants, "Convertible Securities") are issued by us other than in connection with certain excluded securities (as defined in the Note and the Warrant and which include a Qualified Financing and stock awards under our 2009 Equity Incentive Stock Plan), the conversion price of the Note and the Warrants will be reduced to reflect the "dilutive" effect of each such issuance (or deemed issuance upon conversion, exercise or exchange of such Convertible Securities) of our common stock relative to the holders of the Note and the Warrants.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

Because the convertible debentures included detachable warrants that were immediately exercisable at an exercise price on the date of loan at $0.23 per share, which was less than the market value of the shares on that date of $0.29 per share, we determined that warrants to have fair value utilizing the Black-Scholes option-pricing model in excess of the notes' proceeds of $2,500,000. We have used the following assumptions in the Black Scholes option pricing model to determine the fair value of the warrants: (i) dividend yield of 0%; (ii) expected volatility of 41%-506%; (iii) average risk free interest rate of 3.8%; and, (iv) expected life of 5 months. Consequently, we determined that the value of the warrants to be $2,500,000, the amount of the proceeds of the convertible note, which we credited to additional paid-in capital. The fair value of the immediately convertible warrants is being charged to interest expense and accreted to the convertible debenture in the accompanying financial statements from the date of the loan, April 7, 2009, to the extended maturity date of August 30, 2009. For the three months ended June 30, 2009, we charged $493,096 to interest expense in our Statement of Operations. This amount was accreted to the convertible debenture liability on our Balance Sheet at June 30, 2009.

In connection with the Financing, Steven Gluckstern, our Chairman, President, Chief Executive Officer and Chief Financial Officer, and a consultant of ours entered into a participation arrangement with the Lender whereby Mr. Gluckstern and the consultant invested $425,000 and $100,000, respectively with the Lender and shall have a right to participate with the Lender in the Note and the Warrant. As a result of such relationship, our Board of Directors, including its independent members, approved the transactions contemplated by the Loan Agreement.

NOTE 3 - DEFERRED REVENUE

At June 30, 2009, our deferred revenue account balance of $35,640 represents funds received from a customer for an extended one year service contract fee beginning October 1, 2009. Beginning October 1, 2009, we will amortize this amount over 12 months on a straight-line basis.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

NOTE 4 - RELATED PARTY TRANSACTIONS

MANAGEMENT SERVICES AGREEMENT

We entered into a management services agreement, dated as of August 15, 2001, with ADM Tronics Unlimited, Inc. ("ADM) under which ADM provides us and its subsidiaries, Sonotron Medical Systems, Inc. and Pegasus Laboratories, Inc., with management services and allocates portions of its real property facilities for use by us and the other subsidiaries for the conduct of our respective businesses.

The management services provided by ADM under the management services agreement include administrative, technical, engineering and regulatory services with respect to our products. We pay ADM for such services on a monthly basis pursuant to an allocation determined by ADM based on a portion of its applicable costs plus any invoices it receives from third parties specific to us. As we have added employees to our marketing and sales staff and administrative staff following the consummation of initial public offering, our reliance on the use of the management services of ADM has been reduced.

We also use office, manufacturing and storage space in a building located in Northvale, NJ, currently leased by ADM, pursuant to the terms of the management services agreement to which we, ADM and two of ADM's subsidiaries are parties. Pursuant to the management services agreement, ADM determines, on a monthly basis, the portion of space utilized by us during such month, which may vary from month to month based upon the amount of inventory being stored by us and areas used by us for research and development, and we reimburse ADM for our portion of the lease costs, real property taxes and related costs based upon the portion of space utilized by us. We have incurred approximately $10,000 and $16,000 for the use of such space during the quarters ended June 30, 2009 and 2008, respectively.

ADM determines the portion of space allocated to us and each subsidiary on a monthly basis, and we and the other subsidiaries are required to reimburse ADM for our respective portions of the lease costs, real property taxes and related costs.

We have incurred approximately $11,000 and $18,500 of general and administrative expense representing ADM's allocations for management services and the use of real property provided to us by ADM pursuant to the management services agreement during the quarters ended June 30, 2009 and 2008, respectively. In addition, billings by us to ADM for general and administrative expenses amounted to $4,250 and $0 during the quarters ended June 30, 2009 and 2008, respectively.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

MANUFACTURING AGREEMENT

We, ADM and one subsidiary of ADM, Sonotron Medical Systems, Inc., are parties to a second amended and restated manufacturing agreement. Under the terms of the agreement, ADM has agreed to serve as the exclusive manufacturer of all current and future medical and non-medical electronic and other devices or products to be sold or rented by us. For each product that ADM manufactures for us, we pay ADM an amount equal to 120% of the sum of (i) the actual, invoiced cost for raw materials, parts, components or other physical items that are used in the manufacture of the product and actually purchased for us by ADM, if any, plus
(ii) a labor charge based on ADM's standard hourly manufacturing labor rate, which we believe is more favorable than could be attained from unaffiliated third-parties. We generally purchase and provide ADM with all of the raw materials, parts and components necessary to manufacture our products and as a result, the manufacturing fee we pay to ADM generally is 120% of the labor rate charged by ADM. On April 1, 2007, we instituted a procedure whereby ADM invoices us for finished goods at ADM's costs plus 20%.

Under the terms of the agreement, if ADM is unable to perform its obligations under our manufacturing agreement or is otherwise in breach of any provision of our manufacturing agreement, we have the right, without penalty, to engage third parties to manufacture some or all of our products. In addition, if we elect to utilize a third-party manufacturer to supplement the manufacturing being completed by ADM, we have the right to require ADM to accept delivery of our products from these third-party manufacturers, finalize the manufacture of the products to the extent necessary and ensure that the design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process have been met. Although we believe that there are a number of third-party manufacturers available to us, we cannot assure you that we would be able to secure another manufacturer on terms favorable to us or at all or how long it will take us to secure such manufacturing. The initial term of the agreement expired on March 31, 2009, subject to automatic renewals for additional one-year periods, and which was renewed through March 31, 2010, unless either party provides three months' prior written notice to the other prior to the end of the relevant term of its desire to terminate the agreement.

We purchased approximately $40,000 and $325,000 of finished goods and certain components from ADM at contracted rates during the quarters ended June 30, 2009 and 2008, respectively.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

SERVICES AGREEMENT

Effective February 1, 2008, we entered into an agreement to share certain information technology (IT) costs with ADM. During the quarters ended June 30, 2009 and 2008, there have been no cost reimbursements under this agreement.

Effective August 1, 2009, we entered into an agreement with ADM to provide the following services and which cancels our Management Services and Services agreements described above:

O ADM will provide us with engineering services, including quality control and quality assurance services along with regulatory compliance services, warehouse fulfillment services and network administration services including hardware and software services.

O ADM will be paid at the rate of $26,000 per month by us for these services and the four full time engineers and three part time engineers currently employed by us will be terminated by us.

O The services agreement may be cancelled by either party upon sixty days notice.

Our activity with ADM for the quarter ended June 30, 2009 is summarized as follows:

Balance, beginning of period $ 104,321

Advances to ADM --
Purchases from ADM (40,127)
Charges to ADM 4,250
Charges from ADM (10,856)
Payments to ADM 18,263
Payments from ADM (3,296)
 ---------

Balance, end of period $ 72,555
 =========

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

NOTE 5 - CONCENTRATIONS

We maintain cash balances which, at times, exceed federally insured limits. During the three month period ended June 30, 2009, four customers accounted for 57% of our direct sales revenue, two customers accounted for 100% of our rental revenue and one customer accounted for 100% of our sales and revenue share on RecoverCare contract. During the three month period ended June 30, 2008, three customers accounted for 86% of our direct sales revenue, two customers accounted for 59% of our rental revenue and one customer accounted for 100% of our licensing sales and fees revenue. As of June 30, 2009, two customers accounted for 87% of our accounts receivable and as of June 30, 2008, one customer accounted for 39% for our accounts receivable. The loss of these major customers could have a material adverse impact on our operations and cash flow.

NOTE 6 - RECENT ACCOUNTING PRONOUNCEMENTS

On October 10, 2008, the FASB issued Staff Position ("FSP") FAS 157-3, Determining the Fair Value of a Financial Asset When the Market for That Asset Is Not Active. This FSP clarifies the application of FASB Statement No. 157, Fair Value Measurements, in a market that is not active and provides an example to illustrate key considerations in determining the fair value of a financial asset when the market for that financial asset is not active. We have completed our evaluation of the impact of the effect of the adoption of FSP FAS 157-3, and have determined it would have no impact on the Company's financial position, results of operations or cash flows.

In December 2007, the FASB issued SFAS No. 141R, "Business Combinations". This standard establishes principles and requirements for how an acquirer recognizes and measures in its financial statements the identifiable assets acquired, the liabilities assumed, any non-controlling interest in the acquired entity and the goodwill acquired. This statement also establishes disclosure requirements which will enable users to evaluate the nature and financial effects of the business combination. SFAS No.141R is effective for us for acquisitions made after April 1, 2009. The adoption of SFAS No. 141R has not had an impact on our condensed consolidated financial statements. In December 2007, the FASB issued SFAS No. 160, "Non-controlling Interests in Consolidated Financial Statements". This standard outlines the accounting and reporting for ownership interest in a subsidiary held by parties other than the parent. SFAS No. 160 was adopted April 1, 2009, and did not have an impact on our condensed consolidated financial statements.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

SFAS 165. In May 2009, the FASB issued FASB Statement No. 165, SUBSEQUENT EVENTS ("SFAS 165"), which establishes general standards of and accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. This SFAS was effective for interim and annual periods ending after June 15, 2009. The adoption of SFAS 165 had no impact on the Company's financial condition, results of operations or cash flows.

In June 2009, the Financial Accounting Standards Board (FASB) issued SFAS No. 168, "The FASB Accounting Standards CodificationTM and the Hierarchy of Generally Accepted Accounting Principles--a replacement of FASB Statement No. 162," (SFAS 168). SFAS 168 replaces SFAS No. 162, "The Hierarchy of Generally Accepted Accounting Principles," and establishes the FASB Accounting Standards CodificationTM (Codification) as the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in conformity with GAAP. Rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws are also sources of authoritative GAAP for SEC registrants. The FASB will no longer issue new standards in the form of Statements, FASB Staff Positions, or Emerging Issues Task Force Abstracts; instead the FASB will issue Accounting Standards Updates. Accounting Standards Updates will not be authoritative in their own right as they will only serve to update the Codification. The issuance of SFAS 168 and the Codification does not change GAAP. SFAS 168 becomes effective for the Company for the period ending September 30, 2009. Management has determined that the adoption of SFAS 168 will not have an impact on its consolidated financial statements and will only present the challenge of disclosing the Company's accounting positions in accordance with the Codification.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

IVIVI TECHNOLOGIES, INC.
NOTES TO FINANCIAL STATEMENTS -- (CONTINUED)
JUNE 30, 2009
(UNAUDITED)

NOTE 7 - LEGAL PROCEEDINGS

On August 17, 2005, we filed a complaint against Conva-Aids, Inc. t/a New York Home Health Care Equipment, or NYHHC, and Harry Ruddy in the Superior Court of New Jersey, Law Division, Docket No. BER-L-5792-05, alleging breach of contract with respect to a distributor agreement that we and NYHHC entered into on or about August 1, 2004. On April 30, 2008, during a conference before the Hon. Brian R. Martinotti J.S.C. all claims were settled and the terms of the settlement were placed on the record. The settlement calls for the defendants to dismiss with prejudice all counterclaims filed against us and to pay us the sum of $120,000 in installments. The terms provide for an initial payment of $15,000 and the balance to be paid in equal monthly installments of $5,000. In the event of default defendants shall be liable for an additional payment of $30,000, interest at the rate of 8% per annum as well as costs and attorney's fees. The settlement was documented in a written agreement executed by the parties and the initial payment of $15,000 was paid on June 18, 2008. The defendants defaulted on the payment due July 2008 and we were advised that the defendants filed for protection under Chapter 11 of the United States Bankruptcy Code on July 21, 2008. As of June 30, 2009, we have only recognized the cash received. We have filed our proof of claim with the Bankruptcy Court.

On January 19, 2009, the arbitrator rendered the award and found in our favor and determined that no additional fees were owed by Ivivi to Stonefield. The arbitrator further found Ivivi to be the prevailing party. The award is final. As a result, at March 31, 2009, we reversed $105,707 which we previously included in professional fees and accrued expenses for invoices received by us during the quarters ended March 2006 and December 2005. The entire matter was settled at mediation on June 23, 2009. We agreed to accept payment of $350,000 in settlement of any and all claims and the parties agreed to dismiss all pending suits. The settlement was a compromise and Stonefield Josephson did not admit liability. At June 30, 2009 we recorded the settlement in our Balance Sheet as Receivable Relating to Litigation Settlement and as a credit to professional fees - legal in General and Administrative Expense in our Statement of Operations for the year ended March 31, 2009. We received two checks totaling $350,000 on July 7, 2009 in payment of the settlement.

Other than the foregoing, we are not a party to, and none of our property is the subject of, any pending legal proceedings other than routine litigation that is incidental to our business.

NOTE 8 - SUBSEQUENT EVENTS

Subsequent Events have been evaluated through September 21, 2009, the date the financial statements were filed with the Securities and Exchange Commission ("SEC").

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THE FOLLOWING DISCUSSION CONTAINS FORWARD-LOOKING STATEMENTS AND INVOLVES NUMEROUS RISKS AND UNCERTAINTIES, INCLUDING, BUT NOT LIMITED TO, THOSE DESCRIBED

UNDER "ITEM 1A. BUSINESS-RISK FACTORS" OF OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED MARCH 31, 2009. ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE CONTAINED IN ANY FORWARD-LOOKING STATEMENTS. THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH THE AUDITED FINANCIAL STATEMENTS AND NOTES THERETO INCLUDED ELSEWHERE IN THIS QUARTERLY REPORT ON FORM 10-Q.

SUPERVISION AND REGULATION -- SECURITIES AND EXCHANGE COMMISSION

We maintain a website at www.ivivitechnologies.com. We make available free of charge on our website all electronic filings with the Securities and Exchange Commission (including proxy statements and reports on Forms 8-K, 10-K and 10-Q and any amendments to these reports) as soon as reasonably practicable after such material is electronically filed with or furnished to the Securities and Exchange Commission. The Securities and Exchange Commission maintains an internet site (http://www.sec.gov) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the Securities and Exchange Commission.

We have also posted policies, codes and procedures that outline our corporate governance principles, including the charters of the board's audit and nominating and corporate governance committees, and our Code of Ethics covering directors and all employees and the Code of Ethics for senior financial officers on our website. These materials also are available free of charge in print to stockholders who request them in writing. The information contained on our website does not constitute a part of this report.

OVERVIEW

We are an early-stage medical technology company focusing on designing, developing and commercializing proprietary electrotherapeutic technologies. Electrotherapeutic technologies employ pulsed electromagnetic signals for various medical therapeutic applications.

Based on mathematical and biophysical models of the electrochemical properties of specific biochemical signaling pathways, we develop and design proprietary tPEMF signals. Research using our tPEMF signals has suggested, and we believe, that these signals improve specific physiological processes, including those that generate the body's natural anti-inflammatory response, as well as tissue repair. Our tPEMF technology is currently utilized to address pathological conditions, including post operative pain and edema. We are also developing applications for increasing angiogenesis (new blood vessel growth), a critical component for tissue growth and repair.

We attempt to protect our technology and products through patents and patent applications. We have built a portfolio of patents and applications covering our technology and products, including its hardware design and methods. As of the date of this report, we have two issued U.S. patents, one petition pending for one issued U.S. patent and sixteen non-provisional pending U.S. patent applications covering various embodiments and end use indications for tPEMF and related signals and configurations.

Our medical devices are subject to extensive and rigorous regulation by the FDA, as well as other federal and state regulatory bodies. Our currently marketed devices, the SofPulse M-10, Roma and Torino PEMF products are cleared by the FDA for the palliative treatment of post-operative pain and edema in superficial soft tissue. Our devices are also CE marked Conformite Europeenne), cleared by Health Canada, and ready for commercialization in the European Union ("EU") and Canada for the promotion of wound healing, reduction of pain and post-operative edema. Additionally, The Centers for Medicare and Medicaid Services, ("CMS") provides coverage for regenerative chronic wound (e.g., diabetic ulcers) healing in medical center settings.

In addition, the FDA could subject us to other sanctions set forth under "Government Regulation."

Our products consist of the following three components:

o the proprietary targeted pulsed electromagnetic field (tPEMF) signal;

o a signal generator; and

o applicators.

The signal generator produces a specific tPEMF signal that is pulsed through the applicator. The applicator transmits the tPEMF signal into the soft tissue target, penetrating medical dressings, casts, coverings, clothing and virtually all other non-metallic materials. Our products can be used immediately following acute injury, trauma and surgical wounds, as well as in chronic conditions, and requires no alteration of standard clinical practices to accommodate the therapy provided by tPEMF. We have performed rigorous scientific and clinical studies designed to optimize tPEMF signal parameters. These studies have allowed us to develop portable, easy to use products, which have greatly expanded post-operative applications. Product cost has been reduced which may lower the cost of healthcare utilizing our product. We continue to focus our research and development activities on optimizing the signal parameters of our tPEMF technology in order to produce improved clinical outcomes and smaller more efficient, less costly, products utilizing less power.

Since the mid-1990s, our products have been used in over 1,000,000 treatments (15 minute application to a single target area of a patient is one treatment) by healthcare professionals on medical conditions, such as:

o acute or chronic wounds, including post surgical wounds;

o edema and pain following plastic and reconstructive surgery; and

o pain associated with the inflammatory phase of chronic conditions.

We are currently a party to, and intend to continue to seek, agreements with distributors to assist us in the marketing and distribution of our products. As of the date of this report, we have engaged two domestic third-party distributors to assist us in marketing our products in the United States in the chronic wound care market and one distributor in Mexico to assist us in marketing our products. We are also actively pursuing exclusive arrangements with strategic partners we believe have leading positions in our target markets, in order to establish nationwide, and in some cases worldwide, marketing and distribution channels for our products. Generally, under these arrangements, the strategic partners would be responsible for marketing, distributing and selling our products while we continue to provide the related technology, products and technical support. Through this approach, we expect to achieve broader marketing and distribution capabilities in multiple target markets.

GOING CONCERN

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, we had a net loss of $1,846,584 and $2,202,315, respectively, for the quarters ended June 30, 2009 and 2008 and a working capital deficiency of $267,591 at June 30, 2009. We had a net loss of $7,333,604 and $7,503,091, respectively, for the fiscal years ended March 31, 2009 and 2008 and a working capital deficiency of $256,136 at March 31, 2009. At June 30, 2009, we had cash balances of approximately $772,000 which is not sufficient to meet our current cash requirements for the next twelve months. On April 7, 2009, we closed on a $2.5 million loan with Emigrant Capital Corp. (see Note 2 - Loan Agreement). However, we were not able to generate sufficient cash flow from our operations to repay principal on this loan of $2,500,000 plus interest on August 30, 2009.

On September 2, 2009, we announced that we had entered into a Forbearance Agreement (the "Forbearance Agreement") dated August 31, 2009 with Emigrant Capital Corp. (the "Lender"). Pursuant to the terms of the Forbearance Agreement, the Lender had agreed to forbear, through September 9, 2009 (unless a termination event occured under the Forbearance Agreement), from requiring us to repay the principal and interest due under the Convertible Promissory Note (the "Note") in the principal amount of $2.5 million. The maturity date under the Note was August 30, 2009. The Forbearance Agreement also provided for an increase in the interest rate under the Note to the lesser of (i) 18% or (ii) the maximum rate permitted by law during the forbearance period. The Lender agreed to the forbearance in order to provide us with the ability to continue (i) negotiating the previously announced potential transaction with Ajax Capital, LLC ("Ajax"), an entity owned by Steven Gluckstern, our Chairman, President, Chief Executive Officer and Chief Financial Officer, and
(ii) solicit other proposals.

There can be no assurance that we will be able to complete the negotiations of the proposed Asset Purchase Agreement or the proposed Amended and Restated Forbearance Agreement or what the final terms under such agreements will be. In addition, even if we enter into the Asset Purchase Agreement, we may not be able to complete the transactions contemplated by such proposed Asset Purchase Agreement. In the event the transaction with the Buyer is completed, following the closing, it is likely that our liabilities will exceed our available cash and our board of directors may elect to liquidate us and utilize our available cash and assets to repay our outstanding creditors to the extent of our remaining assets and then distribute any remaining assets, if any, to our shareholders. In addition, following the closing we will remain liable under our lease for our Montvale, New Jersey office. The lease, which has a monthly rent of $15,613, will terminate in October 2014. Payments on the lease are current of the date of this filing.

Additional fees may be due Foundation in the event of a Superior Proposal or other future successful financing or other transactions by us.

Loan Agreement

On April 7, 2009, we closed on our $2.5 million loan (the "Financing") with the Lender. Under the terms of the loan agreement between us and the Lender (the "Loan Agreement"), we have borrowed an aggregate of $2.5 million. Borrowings under the Financing are evidenced by a note (the "Note"), which bears interest at a rate of 12% per annum (which, as previously disclosed, increased to 18% after August 31, 2009 in connection with the Forbearance Agreement described in Note 1). See Note 1 for a description of the Forbearance Agreement. The Note is currently convertible into our common stock at a conversion price of $0.23 per share.

Nasdaq Delisting

On June 23, 2009, our common stock was suspended from trading on the Nasdaq Stock Market. On June 26, 2009, our common stock commenced trading on the OTC Bulletin Board under the symbol IVVI.OB.

FDA MATTERS

On April 3, 2008, we filed a 510(k) submission with the Food and Drug Administration (FDA) for a small, compact transcutaneous electrical nerve stimulation (TENS) product utilizing our targeted pulsed electromagnetic field (tPEMF) therapy technology for the symptomatic relief and management of chronic, intractable pain, for relief of pain associated with arthritis and for the adjunctive treatment of post-surgical and post-trauma acute pain. The FDA requested additional information from us in a letter dated April 25, 2008. During October 2008, we requested a voluntary withdrawal of this 510(k).

On December 15, 2008, we announced that we had received FDA 510(k) marketing clearance for our currently marketed tPEMF therapeutic SofPulse products.

PMA or a notice of completion of a Product Development Protocol ("PDP"), or whether the device should be reclassified into class I or II. Summaries and citations were due by August 7, 2009. We submitted our summary with citations to the FDA on August 7, 2009 for our shortwave diathermy devices not generating deep heat, complying with this order. Our products are currently marketed during this process.

We continue to be engaged in research and development activities for additional medical applications of our technology and we expect to file 510(k) submissions or other marketing applications for such additional uses in the future.

RECOVERCARE CONTRACT

On December 18, 2008, we signed a distribution agreement with RecoverCare (the "Contract") to exclusively sell or rent our products into long term acute care hospitals (LTACHS) in the United States and the non-exclusive right to sell or rent our products into acute care facilities and Veterans Administration long term care facilities in the Unites States.

Effective January 1, 2009, we transferred our rental agreements with current customers in these markets to RecoverCare. The Contract has a three year term and the distribution and revenue share portion of the Contract is effective January 1, 2009, with an upfront fee to RecoverCare of $26,000 for certain expenses incurred by them on our behalf. Under the terms of the Contract, we have an obligation to repurchase new Roma units for $535 from RecoverCare in the event the Contract is terminated by mutual consent of the parties. At the termination of the Contract, used Roma units may be purchased by us at reduced rates at our discretion.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Estimates are used for, but not limited to, the accounting for the allowance for doubtful accounts, inventories, income taxes and loss contingencies. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates under different assumptions or conditions.

We believe the following critical accounting policies, among others, may be impacted significantly by judgment, assumptions and estimates used in the preparation of our financial statements:

o We recognize revenue from rental and direct sale of our products from distributors of our products and a revenue share arrangement with RecoverCare.

o Rental revenue is recognized as earned on either a monthly or pay-per-use basis in accordance with individual customer agreements or in accordance with our distributor agreements. Rental revenue recognition commences after the end of the trial period. All of our rentals are terminable by either party at any time.

o Direct sales revenue is recognized when our products are shipped to end users including medical facilities and distributors. Shipping and handling charges and costs have not been material. We have no post shipment obligations except the warranty we provide with each unit and sales returns have been immaterial.

o We record our sales and revenue share in our agreement with RecoverCare as follows:

Rental accounts we serviced as of January 1, 2009 will continue to be serviced by RecoverCare and we will share the revenue collected by RecoverCare on these accounts subject to the terms of the Contract. Our revenue share on these accounts is recorded by us upon receipt by us of the rental invoices sent by RecoverCare to these customers.

After January 1, 2009, RecoverCare will request Roma units from us for rental or sales to their customers. RecoverCare has agreed to pay us an upfront fee of $535 for each Roma unit sent to them which is recorded by us as deposits from RecoverCare in Accounts Payable and Accrued Expenses in our Balance Sheet and these Roma units are included in Equipment in Use or Under Rental Agreements in our Balance Sheet until such time as we are notified by RecoverCare that the Roma unit is "in use" by a customer of RecoverCare. Once we receive notification that a Roma unit is "in use", we record the $535 in Sales and Revenue Share on RecoverCare Contract and our cost to Cost of Sales on RecoverCare Contract in our Statement of Operations.

In addition, we record a revenue share (a percentage of the amount invoiced by RecoverCare less the $535 upfront fee previously received), in Sales and Revenue Share on RecoverCare Contract in our Statement of Operations, based upon the Contract, each month upon notification from RecoverCare that a Roma unit has been rented by their customer and a copy of the invoice is sent to us by RecoverCare. In the event RecoverCare sells a Roma unit, then we record the sale in Sales and Revenue Share on RecoverCare Contract in our Statement of Operations at fixed prices, as defined in the Contract, for the sale of a Roma unit by RecoverCare.

o We record in our Accounts Payable and Accrued Expenses on our Balance Sheet the deposits received from RecoverCare which represent the upfront fee of $535 for each Roma unit held by RecoverCare and which were not placed into service by them.

o We provide an allowance for doubtful accounts determined primarily through specific identification. We review our long lived assets for impairment annually and at March 31, 2009, no impairment was noted.

o Our products held for sale are included in our Balance Sheet under "Inventory." At June 30, 2009, we also had equipment in use or under rental agreements which consists of our electroceutical units and accessories rented to third parties and Roma units held by RecoverCare that were not "in use". Rented equipment is depreciated on a straight-line basis over three years, the estimated useful lives of the units.

o We apply Statement of Financial Accounting Standards No. 128, "Earnings Per Share" (FAS 128). Net loss per share is computed by dividing net loss by the weighted average number of common shares outstanding plus common stock equivalents representing shares issuable upon the assumed exercise of stock options and warrants. Common stock equivalents were not included for the reporting periods, as their effect would be anti-dilutive.

o In April 2006, we adopted the fair value recognition provisions of SFAS No. 123(R), Accounting for Stock-based Compensation, to account for compensation costs under our stock option plans. We previously utilized the intrinsic value method under Accounting Principles Board Opinion No. 25, Accounting for Stock Issued to Employees (as amended). As of June 30, 2009, we have used the following assumptions in the Black Scholes option pricing model: (i) dividend yield of 0%; (ii) expected volatility of 44%-287.5%; (iii) average risk free interest rate of 1.78%-5.03%; (iv) expected life of 1 to 6.5 years; and (v) estimated forfeiture rate of 5%.

o We apply FASB No. 157, "Fair Value Measurements" (Statement No. 157), which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Statement No. 157 applies to other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. In February 2008, the FASB issued FASB Staff Position 157-2, which provides for a one-year deferral of the provisions of Statement No. 157 for non-financial assets and liabilities that are recognized or disclosed at fair value in the financial statements on a non-recurring basis. Effective April 1, 2008, we adopted the provisions of Statement No. 157 for financial assets and liabilities, as well as for any other assets and liabilities that are carried at fair value on a recurring basis. The adoption of the provisions of Statement No. 157 related to financial assets and liabilities and other assets and liabilities that are carried at fair value on a recurring basis did not materially impact the company's financial position and results of operations. For certain of our financial instruments, including accounts receivable, inventories, accounts payable and accrued expenses, the carrying amounts approximate fair value due to their relatively short maturities.

o We apply the Financial Accounting Standards No. 159 ("FAS 159"), The Fair Value Option for Financial Assets and Financial Liabilities, which permits entities to choose to measure many financial instruments and certain other items at fair value which are not currently required to be measured at fair value. Effective April 1, 2008, we adopted the provisions of Statement No. 159 for financial assets and liabilities. The adoption of the provisions of Statement No. 159 related to financial assets and liabilities that are carried at fair value on a recurring basis did not materially impact the company's financial position and results of operations.

o We use the fair value method for equity instruments granted to non-employees and use the Black Scholes option value model for measuring the fair value of warrants and options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the periods in which the related services are rendered.

RECENT ACCOUNTING PRONOUNCEMENTS

In March 2008, the FASB issued SFAS No. 161, "Disclosures about Derivative Instruments and Hedging Activities - An Amendment of FASB Statement No. 133". This statement is intended to improve financial reporting of derivative instruments and hedging activities by requiring enhanced disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS 133 and its related interpretations and (c) how derivative instruments and related hedged items affect an entity's financial position, financial performance and cash flows. The provisions of SFAS 161 are effective for fiscal years beginning after November 15, 2008. SFAS 161 was adopted on April 1, 2009 and did not have an impact on our condensed consolidated financial statements. SFAS 165. In May 2009, the FASB issued FASB Statement No. 165, SUBSEQUENT EVENTS ("SFAS 165"), which establishes general standards of and accounting for and disclosure of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. This SFAS was effective for interim and annual periods ending after June 15, 2009. The adoption of SFAS 165 had no impact on the Company's financial condition, results of operations or cash flows.

Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.

RESULTS OF OPERATIONS

QUARTER ENDED JUNE 30, 2009 COMPARED TO QUARTER ENDED JUNE 30, 2008

NET LOSS - Net loss decreased $355,731 to $1,846,584, or $0.16 per share, for the quarter ended June 30, 2009 compared to $2,202,315, or $0.21 per share, for the quarter ended June 30, 2008. The decrease in net loss primarily resulted from (i) decreases in sales and marketing expenses of $584,651, or 86%, (ii) decreases in general and administrative expenses of $448,337, or 35%, (iii) decreases in cost of licensing sales on Allergan contract of $129,770, or 100%,
(iv) decreases in cost of rental revenue of $10,214, or 100%, and, (v) decreases in cost of direct sales of $5,952, or 49%, and, (vi) decreases in research and development expenses of $37,313, or 7%, partially offset by (vii) decreases in revenues of $248,838, or 65%, (vii) increases in the cost of sales on RecoverCare contract $12,373, or 100%, (ix) decreases in interest income of $41,449, or 92%, and (x) increase in interest expense of $557,846, or 100%.

REVENUE - Total revenue decreased by $248,838, or 65%, to $134,358 for the quarter ended June 30, 2009 as compared to $358,196 for the quarter ended June 30, 2008. The decrease in revenue was due to (i) a decrease in our licensing sales and fees of $115,411, or 100%, as a result of our termination of our agreement with Allergan on November 19, 2008, (ii) a decrease in our rental revenue of $164,356, or 97%, as a result of the reduction in our sales and marketing staff and the transition of our wound care marketing efforts under the terms of our agreement with RecoverCare, and (iii) a decrease in our direct sales of $60,348, or 61%, as a result of the reduction in our sales and marketing staff, partially offset by an increase in our sales and revenue share on the RecoverCare contract of $91,277, or 100%.

RecoverCare purchases Torinos, Applicators and other disposable equipment from us at stated prices and revenue is recorded in Sales and Revenue Share on RecoverCare Contract at the time this inventory is shipped to RecoverCare. Rental accounts we serviced as of January 1, 2009 will continue to be serviced by RecoverCare and we will share the revenue collected by RecoverCare on these accounts subject to the terms of the Contract. Our revenue share on these accounts is recorded by us upon receipt by us of the rental invoices sent by RecoverCare to these customers.

Under the terms of the Contract, we shipped 64 Roma units to RecoverCare during the period January 1, 2009 through June 30, 2009, of which 37 Roma units were "in use" by RecoverCare customers at June 30, 2009. During the quarter ended June 30, 2009, we recorded $10,700 as Sales and Revenue Share on RecoverCare Contract in our Statement of Operations for the 20 Roma units that were placed "in use" during the quarter. In addition, we recorded $10,867 as Sales and Revenue Share on RecoverCare Contract in our Statement of Operations from the sale of Torinos, Applicators and other disposable equipment to RecoverCare during the quarter ended June 30, 2009. Further, we recorded $69,710 as Sales and Revenue Share on RecoverCare Contract in our Statement of Operations for the quarter ended June 30, 2009. This revenue represents our portion of the revenue share for the period April through June 2009, from accounts we transferred to RecoverCare on January 1, 2009.

At June 30, 2009, the balance of our Equipment in Use or Under Rental Agreements on our Balance Sheet includes $7,560 which is the value of the 27 Roma units held by RecoverCare on that date and which, were not placed into service by them at June 30, 2009.

At June 30, 2009, our Accounts Payable and Accrued Expenses on our Balance Sheet includes $14,445 of deposits received from RecoverCare which is the upfront fee of $535 for each of the 27 Roma units held by RecoverCare on that date and which, were not placed into service by them at June 30, 2009.

We recorded $0 and $94,277 in the quarters ended June 30, 2009 and 2008, respectively, which represented sales of SofPulse units to Allergan and we recorded $0 and $15,625 in the quarters ended June 30, 2009 and 2008, respectively, which represents the amortized portion of the initial milestone payment of $500,000 that was received from Allergan in November 2006 and is included in sales to licensee and fees on our Statements of Operations. Royalties received from Allergan during the quarters ended June 30, 2009 and 2008 were $0 and $5,509, respectively. On November 19, 2008 we terminated our agreement with Allergan.

COST OF RENTALS - Cost of rentals decreased $10,214, or 100%, to $0 for the quarter ended June 30, 2009 from $10,514 for the quarter ended June 30, 2008, primarily as a result of the implementation of our agreement with RecoverCare. Our cost of rentals for the quarter ended June 30, 2008 consisted of product costs of $2,531, freight of $1,473 and depreciation on our Roma units under rental agreements of $6,210.

COST OF DIRECT SALES - Cost of direct sales decreased $5,952 or 49%, to $6,308 for the quarter ended June 30, 2009 from $12,260 for the quarter ended June 30, 2008 as a result of the implementation of our agreement with RecoverCare and the mix of products sold and the unit cost of these products during the quarter ended June 30, 2009 versus the prior year period.

Purchases of finished goods and certain components from ADM were $40,127 and $324,614 for the quarters ended June 30, 2009 and 2008, respectively.

COST OF SALES ON RECOVERCARE CONTRACT - Cost of sales on RecoverCare contract increased $12,373, or 100%, to $12,373 for the quarter ended June 30, 2009 from $0 for the quarter ended June 30, 2008 as a result of the implementation of our agreement with RecoverCare. Our cost of sales on RecoverCare contract for the quarter ended June 30, 2009 consisted of product costs of $8,201 and depreciation on our Roma units under rental agreements of $4,172.

COST OF LICENSING SALES ON ALLERGAN CONTRACT - Cost of licensing sales decreased $129,770, or 100%, to $0 for the quarter ended June 30, 2009 from $129,770 for the quarter ended June 30, 2008.

We recorded $0 and $129,770 as product cost to cost of licensing sales on Allergan contract for the quarters ended June 30, 2009 and 2008, respectively. The negative gross margin on the sale of our SofPulse units to Allergan was $35,493 for the quarter ended June 30, 2008 as a result of the initial production of the Allergan products.

RESEARCH AND DEVELOPMENT COSTS - Research and development expense decreased $37,313, or 7%, to $493,755 for the quarter ended June 30, 2009 from $531,068 for the quarter ended June 30, 2008. The decrease resulted primarily from decreases in consulting expenses of $37,073, decreases in salary and salary related expenses of $16,340, and decreased patent amortization expense of $22,276 partially offset by increases in research and development studies of $21,073, increases in travel costs of $11,278 and increased share based compensation expense of $8,157.

SELLING AND MARKETING EXPENSES - Sales and marketing expenses decreased $584,651, or 86%, to $92,571, for the quarter ended June 30, 2009 as compared to $677,222 for the quarter ended June 30, 2008. The decrease resulted primarily from decreased salary and salary related costs of $248,177, decreased travel costs of $99,013, decreased commission expenses of $33,297, a decrease in advertising costs of $41,616, decreased marketing costs of $43,957, a decrease in consulting expenses of $60,576, a decrease in bad debt expense of $40,272, a decrease in shipping costs of $7,107, a decrease in warranty and repairs expenses of $3,067, a decrease in share based compensation of $2,420, and decreases in depreciation and amortization expense of $5,877. The decreases in our sales and marketing expenses during the quarter ended June 30, 2009 as compared with the quarter ended June 30, 2008 resulted primarily from the reduction in our sales force of seven sales and sales related administrative personnel which occurred on August 31, 2008 and the implementation of our agreement with RecoverCare.

GENERAL AND ADMINISTRATIVE EXPENSES - General and administrative expenses decreased $448,337, or 35%, to $821,800 for the quarter ended June 30, 2009 as compared to $1,270,137 for the quarter ended June 30, 2008. The decrease resulted primarily from decreases in salary and salary related costs of $120,040, decreased rent and occupancy expenses of $8,353, decreased share based compensation expense of $182,870, decreased investor relations expenses of $41,264, decreased public relations expenses of $32,054, a decrease in accounting fee expense of $43,444, decreased legal fees expense of $64,483 and decreased general office expenses of $19,837 (primarily decreased telephone expenses of $5,719, decreased computer expenses of $8,378 and decreased expenses for office supplies and equipment of $6,347), partially offset by increased consulting expenses of $18,202, increased travel related expenses of $29,960 and increased Nasdaq listing fees expense of $13,950.

INTEREST INCOME - Interest income decreased $41,449, or 92%, to $3,711 from $45,160 as a result of lower cash balances in our money market accounts and lower interest rates on our deposits during the quarter ended June 30, 2009 as compared to the quarter ended June 30, 2008.

INTEREST EXPENSE - Interest expense increased $557,846, or 100%, to $557,846 from $0 as a result of our accrual of interest expense, in the amount of $64,750, on our convertible debt issued to Emigrant Capital Corp. at the default interest rate of 18% per annum and the accretion of the effective interest on the debt discount due to the convertible feature of the note and the valuation of attached warrants in the amount of $493,096.

LIQUIDITY AND CAPITAL RESOURCES

Currently, we have $2.5 million of debt outstanding under our Loan Agreement. On September 2, 2009, we announced that we had entered into a Forbearance Agreement (the "Forbearance Agreement") dated August 31, 2009 with Emigrant Capital Corp. (the "Lender"). Pursuant to the terms of the Forbearance Agreement, the Lender had agreed to forbear, through September 9, 2009 (unless a termination event occured under the Forbearance Agreement), from requiring us to repay the principal and interest due under the Convertible Promissory Note (the "Note") in the principal amount of $2.5 million. The maturity date under the Note was August 30, 2009. The Forbearance Agreement also provided for an increase in the interest rate under the Note to the lesser of (i) 18% or (ii) the maximum rate permitted by law during the forbearance period. The Lender agreed to the forbearance in order to provide us with the ability to continue (i) negotiating the previously announced potential transaction with Ajax Capital, LLC ("Ajax"), an entity owned by Steven Gluckstern, our Chairman, President, Chief Executive Officer and Chief Financial Officer, and (ii) solicit other proposals.

We have had significant operating losses for the quarters ended June 30, 2009 and 2008 as well as for our fiscal years ended March 31, 2009 and 2008. At June 30, 2009, we had an accumulated deficit of approximately $40.4 million. Our continuing operating losses have been funded principally through the proceeds of our private placement financings, our initial public offering and other arrangements. We have generated limited revenues of approximately $134,000 and $383,000 for our quarters ended June 30, 2009 and 2008, and $1.5 million and $1.6 million for our fiscal years ended March 31, 2009 and 2008, respectively, primarily from the rental and sale of our products, and we expect to incur additional operating losses, as well as negative cash flow from operations. Our continuing operating losses have been funded principally through the proceeds of our private placement financings and our IPO as well as our loan from Emigrant Capital Corp. (see "Loan Agreement").

Our financial statements, as contained in this Form 10-Q, have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying financial statements, we had a net loss of $1,846,584 and $2,202,315, respectively, for the quarters ended June 30, 2009 and 2008 and a working capital deficiency of $267,591 at June 30, 2009. We had a net loss of $7,333,604 and $7,503,091, respectively, for the fiscal years ended March 31, 2009 and 2008 and a working capital deficiency of $256,136 at March 31, 2009. In addition, at June 30, 2009, we had cash balances of approximately $772,000 which was not sufficient to meet our cash requirements for the next twelve months.

On April 7, 2009, we closed on a $2.5 million loan with Emigrant Capital Corp. (see "Loan Agreement"). However, we do not expect to be able to generate sufficient cash flow from our operations to meet our continuing obligations. We will need to obtain additional capital to continue to operate and grow our business. In the fourth quarter of 2008, we retained two firms, including Foundation, to assist us in pursuing alternative strategies and financings relating to our business. In December 2008, we terminated our relationship with one of the firms. Through June 30, 2009, we paid $130,000 and issued warrants to one of the entities including $100,000 of fees relating to our Loan Agreement. Additional fees of $150,000 were paid to these entities subsequent to June 30, 2009, including $125,000 of fees relating to our current transaction being negotiated. Additional fees may be due to Foundation in the event of a Superior Proposal or other future successful financing or other transactions by us.

As of June 30, 2009, we had cash and cash equivalents of approximately $772,000 as compared to cash and cash equivalents of approximately $4,788,000 at June 30, 2008.

Net cash used in operating activities was approximately $1.2 million during the quarter ended June 30, 2009 compared to approximately $1.7 million during the quarter ended June 30, 2008.

Net cash used in operating activities during the quarter ended June 30, 2009 resulted primarily from our net loss of approximately $1.8 million during the period, increases in inventory of approximately $17,000 and decreases in accounts payable and accrued expenses of approximately $93,000 partially offset by decreases in accounts receivable of approximately $9,000, decreases in prepaid expenses and other current assets of approximately $102,000, decreases in deposits with and amounts due to affiliates of approximately $32,000, decreases in equipment in use or under rental agreements of approximately $5,000 and by non-cash charges of approximately $612,000.

Net cash used in operating activities during the quarter ended June 30, 2008 resulted primarily from our net loss of approximately $2.2 million, increases in inventory of approximately $138,000, increases, increases in equipment in use or under rental agreements of approximately $8,000 and decreases in accounts payable and accrued expenses of approximately $34,000, partially offset by increases in accounts receivable of approximately $187,000, increases in deposits with and amounts due from affiliate of approximately $97,000, decreases in prepaid expenses and other current assets of approximately $28,000 and by non-cash charges of approximately $363,000.

Net cash used for investing activities during the quarter ended June 30, 2009 resulted primarily from the purchase of and payments for patents and trademarks of approximately $71,000. Net cash used for investing activities during the quarter ended June 30, 2008 resulted from purchases of property, plant and equipment of approximately $8,000 and payments for patents and trademarks of approximately $96,000.

Net cash provided by financing activities was $1,820,000 during the quarter ended June 30, 2009 compared to net cash provided by financing activities of $0 during the quarter ended June 30, 2008. The proceeds of $1,820,000 came from the issuance of convertible debt to Emigrant Capital Corp., net of issuance costs of $180,000 comprised of investment banker fees of $100,000 and legal fees of approximately $80,000.

We are funding approximately $385,000 for additional cardiovascular studies. To this end, during the fiscal year ended March 31, 2009, we paid $100,000 to MD Imaging Network for a Cardiovascular - EFFECT trial and image storage. We did not make any payments to MD Imaging Network for a Cardiovascular - EFFECT trial and image storage during the three months ended June 30, 2009.

Further, we paid $50,000 to Stanford University during fiscal year ended March 31, 2009 and, at June 30, 2009 we have accrued an additional $150,000 for a contribution for studies relating to the cardiovascular research program at Stanford University. The remaining $85,000 has not been paid or accrued by us as of June 30, 2009. We did not make any payments to Stanford University toward this contribution during the three months ended June 30, 2009. These amounts may be increased if we expand our current studies or if we pursue additional studies and we will need to raise additional capital in such circumstances. This research may not be completed within our projected cost and our available funds will limit the amount of research to be performed in the future.

We were a party to a sponsored research agreement with Montefiore Medical Center pursuant to which we funded research in the fields of pulsed electro-magnetic frequencies at Montefiore Medical Center's Department of Plastic Surgery that commenced on October 17, 2004 and expires on December 31, 2009. We were notified prior to our fiscal year ended March 31, 2007, that the research being conducted at Montefiore Medical Center's Department of Plastic Surgery has concluded and this agreement will not be renewed. We expect to receive the data from this study during the fall of 2009. We paid $70,000 during the fiscal year ended March 31, 2009 for this data and, at June 30, 2009 the remaining balance of $20,000 is included in our accrued liabilities in our financial statements.

We fund research in the field of neurosurgery under the supervision of Dr. Casper, of Montefiore Medical Center's Department of Neurosurgery. Dr. Casper also uses our product in this research. The research will be conducted over a period of several years but our funding is determined yearly, based on annual budgets mutually approved. We expensed $75,000 and $83,500 during the quarters ended June 30, 2009 and 2008, respectively, to continue Dr. Casper's research. During the quarters ended June 30, 2009 and 2008, we have paid $79,250 and $0, respectively. This research may not be completed within our projected cost and our available funds will limit the amount of research to be performed in the future.

In June, 2007, we entered into a Research Agreement with Indiana State University to conduct randomized, double-blind animal wound studies to assist us in determining optimal signal configurations and dosing regimens. The total cost of the research studies is approximately $160,000 of which we expensed approximately $12,000 and $18,000 during the quarters ended June 30, 2009 and 2008, respectively. For the quarters ended June 30, 2009 and 2008, respectively, we have paid approximately $0 and $74,000 towards this research and we accrued $40,000 as of June 30, 2009 for the research performed through June 30, 2009 and we expect to expense the remainder, approximately $23,000, during our fiscal year ended March 31, 2010. This research may not be completed within our projected cost and our available funds will limit the amount of research to be performed in the future.

On May 1, 2008 we signed a research agreement with the Henry Ford Health System. The principal investigator, Dr. Fred Nelson in the Department of Orthopedics will study our prototype device using targeted tPEMF signal configurations on human patients, with established osteoarthritis of the knee, who are active at least part of the day. We received IRB approval at The Henry Ford Health System to begin the double- blind randomized controlled study and the institution began enrolling patients during August 2008. The estimated total cost of the research with the Henry Ford Health System is approximately $112,000, of which approximately $53,000 has been incurred by the institution through June 30, 2009. For the quarter ended June 30, 2009, we have paid $0 towards this research and we accrued approximately $26,000 as of June 30, 2009 for the research performed through June 30, 2009. This research may not be completed within our projected cost and our available funds will limit the amount of research to be performed in the future.

We entered into a management services agreement, dated as of August 15, 2001, with ADM under which ADM provides us and its subsidiaries, Sonotron Medical Systems, Inc. and Pegasus Laboratories, Inc., with management services and allocates portions of its real property facilities for use by us and the other subsidiaries for the conduct of our respective businesses.

Under the terms of the agreement, if ADM is unable to perform its obligations under our manufacturing agreement or is otherwise in breach of any provision of our manufacturing agreement, we have the right, without penalty, to engage third parties to manufacture some or all of our products. In addition, if we elect to utilize a third-party manufacturer to supplement the manufacturing being completed by ADM, we have the right to require ADM to accept delivery of our products from these third-party manufacturers, finalize the manufacture of the products to the extent necessary and ensure that the design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process have been met. Although we believe that there are a number of third-party manufacturers available to us, we cannot assure you that we would be able to secure another manufacturer on terms favorable to us or at all or how long it will take us to secure such manufacturing. The initial term of the agreement expires on March 31, 2009, subject to automatic renewals for additional one-year periods, and which was renewed through March 31, 2010, unless either party provides three months' prior written notice to the other prior to the end of the relevant term of its desire to terminate the agreement.

We purchased approximately $40,000 and $325,000 of finished goods and certain components from ADM at contracted rates during the quarters ended June 30, 2009 and 2008, respectively.

Effective August 1, 2009, we entered into an agreement with ADM to provide the following services and which cancels our Management Services, Manufacturing and Services agreements described above:

O ADM will be paid at the rate of $26,000 per month by us for these services and the four full time engineers and three part time engineers currently employed by us will be terminated by us. It is expected that these four full time engineers will be employed by ADM.

O The services agreement may be cancelled by either party upon sixty days notice.

OFF-BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

MARKET RISK RELATED TO INTEREST RATES AND FOREIGN CURRENCY
We are exposed to market risks related to changes in interest rates; however, we believe those risks to be not material in relation to our operations. We do not have any derivative financial instruments.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as such term is defined in Rules
13(d)-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in our Exchange Act reports are recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Management necessarily applies its judgment in assessing the costs and benefits of such controls and procedures, which, by their nature, can provide only reasonable assurance regarding management's control objectives.

As of the end of the period covered by this Quarterly Report on Form 10-Q, we carried out an evaluation, with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Securities Exchange Act Rule 13a-15. Based upon that evaluation as of June 30, 2009, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective, at the reasonable assurance level, in ensuring that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to our management including our Chief Executive Officer and Chief Financial Officer, to ensure that such information is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms.

We will continue to review and evaluate the design and effectiveness of our disclosure controls and procedures on an ongoing basis and to improve our controls and procedures over time and correct any deficiencies that we may discover in the future. Our goal is to ensure that our senior management has timely access to all material financial and non-financial information concerning our business. While we believe the present design of our disclosure controls and procedures is effective to achieve our goals, future events affecting our business may cause us to modify our disclosure controls and procedures.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal controls over financial reporting that occurred during our the fiscal quarter ended June 30, 2009 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

INTEREST RATE RISK

As of June 30, 2009, our cash included approximately $772,000 of money market bank accounts. Due to the fact that money market accounts are available for withdrawals on a daily basis and traditional the investments are of a short-term duration, an immediate 10% change in interest rates would not have a material effect on the fair market value of our money market accounts. Therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our money market accounts. Our loan with Emigrant Capital Corp. is at a fixed interest rate.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

On October 10, 2006, we received a demand for arbitration by Stonefield Josephson, Inc. with respect to a claim for fees for accounting services in the amount of $105,707, plus interest and attorney's fees. Stonefield Josephson had previously invoiced Ivivi for fees for accounting services in an amount which Ivivi refuted. We pursued claims against Stonefield Josephson. We filed a complaint against Stonefield Josephson in the Superior Court of New Jersey Law Division Docket No.BER-l-872-08 on January 31, 2008. A commencement of arbitration notice initiated by Stonefield Josephson was received by us on March 11, 2008. In March and April motions were filed by us and Stonefield Josephson which sought various forms of relief including the forum for resolution of the claims. On June 3, 2008, the court determined that the language in the engagement agreement constituted a forum selection clause and the claims should be decided in California. On June 19, 2008, we filed a complaint against Stonefield Josephson in the Superior Court of California, Los Angeles County. On July 18, 2008, the court denied our request for reconsideration of the order dated June 3, 2008. On January 19, 2009, the arbitrator rendered the award and found in our favor and determined that no additional fees were owed by Ivivi to Stonefield. The arbitrator further found Ivivi to be the prevailing party. The award is final. As a result, at March 31, 2009, we reversed $105,707 which we previously included in professional fees and Accrued expenses for invoices received by us during the quarters ended March 2006 and December 2005. The entire matter was settled at mediation on June 23, 2009. We agreed to accept payment of $350,000 in settlement of any and all claims and the parties agreed to dismiss all pending suits. The settlement was a compromise and Stonefield Josephson did not admit liability. At June 30, 2009 we recorded the settlement in our Balance Sheet as Receivable Relating to Litigation Settlement and as a credit to professional fees - legal in General and Administrative Expense in our Statement of Operations for the year ended March 31, 2009. We received two checks totaling $350,000 on July 7, 2009 in payment of the settlement.

Other than the foregoing, we are not a party to, and none of our property is the subject of, any pending legal proceedings other than routine litigation that is incidental to our business.

ITEM 1A. RISK FACTORS

AN INVESTMENT IN OUR COMMON STOCK IS SPECULATIVE AND INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY CONSIDER THE RISKS DESCRIBED BELOW, TOGETHER WITH THE OTHER INFORMATION CONTAINED IN THIS ANNUAL REPORT ON FORM 10-K, BEFORE BUYING OUR COMMON STOCK. THESE RISKS COULD HAVE A MATERIAL ADVERSE EFFECT ON OUR BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS AND THE VALUE OF OUR COMMON STOCK.

EXCEPT AS SET FORTH BELOW, THERE HAVE BEEN NO MATERIAL CHANGES TO THE RISK FACTORS CONTAINED IN OUR ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED MARCH 31, 2009.

RISKS AFFECTING OUR BUSINESS

IF WE ARE UNABLE TO REPAY OUR OUTSTANDING LOAN BY THE EXTENDED DUE DATE, WE WILL BE IN DEFAULT UNDER OUR LOAN AGREEMENT WITH OUR LENDER

We have $2.5 million of debt outstanding under our loan agreement. The loan matured, plus interest, on August 30, 2009 but, the Lender has granted us a forbearance through September 21, 2009 and we are currently negotiating a further extension.

There can be no assurance that we will be able to complete the negotiations of the proposed Asset Purchase Agreement or the proposed Amended and Restated Forbearance Agreement described in Note 1 of our financial statements or what the final terms under such agreements will be. In addition, even if we enter into the Asset Purchase Agreement, we may not be able to complete the transactions contemplated by such proposed Asset Purchase Agreement. In the event the transaction with the Buyer is completed, following the closing, our board of directors may elect to liquidate us and utilize our available cash and assets to repay our outstanding creditors to the extent of our remaining assets and then distribute any remaining assets, if any, to our shareholders. However, following the closing, it is likely that our liabilities will exceed our available cash. In addition, following the closing we will remain liable under our lease for our Montvale, New Jersey office. The lease, which has a monthly rent of $15,613, will terminate in October 2014. Payments on the lease are current as of the date of this filing.

ITEM 6. EXHIBITS.

Exhibit No. Description
----------- -----------

3.1 Restated Certificate of Incorporation of Ivivi Technologies,
 Inc. (1)

3.2 Amended and Restated By-Laws of Ivivi Technologies, Inc. (1)

4.1 Form of Stock Certificate of Ivivi Technologies, Inc. (2)

4.2 Warrant issued to certain investors (one in a series of
 warrants with identical terms) (3)

4.3 Form of Warrant issued to Placement Agent (3)

4.4 Warrant issued to certain investors (one in a series of
 warrants with identical terms) (4)

4.5 Registration Rights Agreement among Ivivi Technologies, Inc.
 and certain investors (included as Exhibit E to form of
 Subscription Agreement filed as Exhibit 10.19)

4.6 Registration Rights Agreement among Ivivi Technologies, Inc.
 and certain investors (included as Exhibit C to form of
 Subscription Agreement filed as Exhibit 10.20)

4.7 Registration Rights Agreement among Ivivi Technologies, Inc.
 and certain investors (2)

4.8 Form of Warrant issued to consultants (2)

4.9 Form of Warrant issued to certain advisors (2)

4.10 Registration Rights Agreement, dated as of October 15, 2007,
 between Ivivi Technologies, Inc. and the investor named therein
 (11)

10.1 2004 Amended and Restated Stock Option Plan, as amended(1)

10.2 Second Amended and Restated Manufacturing Agreement, dated as
 of June 15, 2006, among Ivivi Technologies, Inc., ADM Tronics
 Unlimited, Inc., and certain subsidiaries of ADM
 TronicsUnlimited, Inc. (6)

10.3 Management Services Agreement, dated August 15, 2001, among
 Ivivi Technologies, Inc., ADM Tronics Unlimited, Inc. and
 certain subsidiaries of ADM Tronics Unlimited, Inc., as amended
 (7)

10.4 Form of Indemnification Agreement between Ivivi Technologies,
 Inc. and each of its directors and officers (9)

 44

10.5 Amended and Restated Voting Agreement among the parties named
 therein (9)

10.6 Agreement, effective as of February 10, 2005, between Ivivi
 Technologies, Inc. and ADM Tronics Unlimited, Inc. (5)

10.7 Master Clinical Trial Agreement, dated as of January 9, 2006,
 between Ivivi Technologies, Inc. and Cleveland Clinic Florida
 (6)

10.8 Form of Distribution Agreement (5)

10.9 Amended and Restated Employment Agreement, dated October 18,
 2007, between Ivivi Technologies, Inc. and Andre' DiMino (13)

10.10 Amended and Restated Employment Agreement, dated October 18,
 2007, between Ivivi Technologies, Inc. and David Saloff (13)

10.11 Employment Agreement, dated as of July 13, 2006, between Ivivi
 Technologies, Inc. and Alan Gallantar (7)

10.12 Amendment to Employment Agreement between Ivivi Technologies
 Inc. and Alan Gallantar dated December 31, 2009

10.13 Option Agreement, dated as of June 16, 2006, between Ivivi
 Technologies, Inc. and Steven M. Gluckstern (6)

10.14 Share Purchase Right Agreement, dated as of November 8, 2005,
 between Ivivi Technologies, Inc. and Steven Gluckstern (6)

10.15 Subscription Agreement between Ivivi Technologies, Inc. and
 certain investors (2)

10.16 Subscription Agreement between Ivivi Technologies, Inc. and
 certain investors (2)

10.17 Exclusive Distribution Agreement, dated as of November 9, 2006,
 between Ivivi Technologies, Inc. and Inamed Medical Products
 Corporation (10) +

10.19 Lease Agreement, dated as of June 18, 2007, between Ivivi
 Technologies, Inc. and Mack-Cali East Lakemont LLC (12)

10.20 Employment Agreement as of December 31, 2008 between Steven M.
 Gluckstern and Ivivi Technologies, Inc.(13)

10.21 Amendment to Employment Agreement dated April 2, 2009 between
 Steven M. Gluckstern and Ivivi Technologies, Inc.(14)

10.22 Amendment to Employment Agreement dated April 2, 2009 between
 Alan Gallantar and Ivivi Technologies, Inc.(14)

10.23 Amendment to Employment Agreement dated April 2, 2009 between
 Andre' DiMino and Ivivi Technologies, Inc.(14)

 45

10.24 Amendment to Employment Agreement dated April 2, 2009 between
 David Saloff and Ivivi Technologies, Inc.(14)

10.25 Loan Agreement dated April 7, 2009 between Emigrant Capital
 Corp. and Ivivi Technologies, Inc.(14)

10.26 Consulting Agreement, dated October 17, 2006, between Ivivi
 Technologies, Inc and Arthur Pilla (12)

10.27 Consulting Agreement, dated January 1, 2004, between Ivivi
 Technologies, Inc. and Berish Strauch, M.D.(3)

10.28 Service Agreement, dated August 1, 2009, between Ivivi
 Technologies, Inc. and ADM Tronics Unlimited, Inc. and
 Subsidiaries *

14.1 Ivivi Technologies, Inc. Code of Ethics for Senior Financial
 Officers, Executive Officers and Directors (2)

31.1 Certification of Chief Executive Officer and Chief Financial
 Officer pursuant to Section 302 of the Sarbanes-Oxley Act of
 2002 *

32 Certification pursuant to 18 U.S.C. Section 1350, as adopted
 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 *

99.1 Audit Committee charter (2)

-----------------

* Filed herewith.

+ Portions of this document have been omitted and filed separately with the Securities and Exchange Commission pursuant to a request or confidential treatment in accordance with Rule 406 of the Securities Act.

(1) Incorporated by reference to Ivivi Technologies, Inc.'s Registration Statement on Form S-8, filed with the Securities and Exchange Commission on February 13, 2007.

(2) Incorporated by reference to Amendment No. 7 to Ivivi Technologies, Inc.'s Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on October 13, 2006.

(3) Incorporated by reference to Ivivi Technologies, Inc.'s Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on February 11, 2005.

(4) Incorporated by reference to Amendment No. 3 to Ivivi Technologies, Inc.'s Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on April 20, 2006.

(5) Incorporated by reference to Amendment No. 2 to Ivivi Technologies, Inc.'s Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on May 13, 2005.

(6) Incorporated by reference to Amendment No. 4 to Ivivi Technologies, Inc.'s Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on June 19, 2006.

(7) Incorporated by reference to Amendment No. 5 to Ivivi Technologies, Inc.'s Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on August 29, 2006.

(8) Incorporated by reference to Amendment No. 1 to Ivivi Technologies, Inc.'s Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on March 3, 2005.

(9) Incorporated by reference to Amendment No. 6 to Ivivi Technologies, Inc.'s Registration Statement on Form SB-2, filed with the Securities and Exchange Commission on September 14, 2006.

(10) Incorporated by reference to Ivivi Technologies, Inc.'s Quarterly Report on Form 10-QSB for the quarter ended September 30, 2006, filed with the Securities and Exchange Commission on December 4, 2006.

(11) Incorporated by reference to Ivivi Technologies, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 16, 2007.

(12) Incorporated by reference to Ivivi Technologies, Inc.'s Annual Report on Form 10-KSB filed with the Securities and Exchange Commission on June 29, 2007.

(13) Incorporated by reference to Ivivi Technologies, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 2, 2009.

(14) Incorporated by reference to Ivivi Technologies, Inc.'s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 8, 2009.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

IVIVI TECHNOLOGIES INC.
(Registrant)

 Dated: September 21, 2008
 By: /s/ Steven Gluckstern
 --------------------------
 Steven Gluckstern President,
 Chief Executive Officer
 (Principal Executive Officer)
 and Chief Financial Officer
(Principal Financial Officer and
 Principal Accounting Officer)

Ivivi Technologies (CE) (USOTC:IVVI)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Ivivi Technologies (CE) Charts.

Ivivi Technologies (CE) (USOTC:IVVI)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

IVVI Ivivi Technologies Inc (CE)

News

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

IVVI Ivivi Technologies Inc (CE)

News

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen